Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Lucid Diagnostics Inc. (LUCD) announced that their President & COO will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference. The webcast will be available on their website, with a replay option for 30 days.

NEW YORK, April 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that Lucid's President & Chief Operating Officer Shaun O'Neil will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 11:00 a.m. E.T.

The fireside chat will be webcast live and can be accessed by visiting the Investor Relations Section of the Lucid Diagnostics website or by clicking here.  A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast. Company management will meet with investors in one-on-one meetings during the conference.

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on cancer prevention, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard^® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool for at-risk patients to mitigate the risks of cancer and cancer deaths through early detection of esophageal precancer.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-participate-in-fireside-chat-at-the-23rd-annual-needham-virtual-healthcare-conference-302110087.html

SOURCE Lucid Diagnostics

When will Lucid Diagnostics' President & COO participate in the fireside chat at the 23rd Annual Needham Virtual Healthcare Conference?

Lucid Diagnostics' President & COO will participate in the fireside chat on Thursday, April 11, 2024, at 11:00 a.m. E.T.

Where can the webcast of the fireside chat be accessed?

The webcast can be accessed by visiting the Investor Relations Section of the Lucid Diagnostics website or by clicking on the provided link.

Will there be a replay option for the webcast?

Yes, a replay of the webcast will be available on the website for 30 days after the live broadcast.

Will company management meet with investors during the conference?

Yes, company management will meet with investors in one-on-one meetings during the conference.